#Deucravacitib
LightNews LightNews
rheumawrite.bsky.social
ReadingRheum 🛋️:

TYK TYK Boom goes #Deucravacitib on SLE🦋

#RheumMadness
🔗 https://buff.ly/4hJ2ii7
💧
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial - PubMed
Deucravacitinib treatment elicited higher response rates for SRI-4 and other end points compared with placebo, with an acceptable safety profile, in adult patients with active SLE.
buff.ly
February 5, 2025 at 1:00 AM